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The role of PPARγ in adipocyte diﬀerentiation has fueled intense interest in the function of this steroid nuclear receptor for
regulation of malignant cell growth and diﬀerentiation. Given the antiproliferative and diﬀerentiating eﬀects of PPARγ ligands
on liposarcoma cells, investigation of PPARγ expression and ligand activation in other solid tumors such as breast, colon, and
prostate cancers ensued. The anticancer eﬀects of PPARγ ligands in cell culture and rodent models of a multitude of tumor types
suggest broad applicability of these agents to cancer therapy. This review focuses on the clinical use of PPARγ ligands, speciﬁcally
the thiazolidinediones, for the treatment and prevention of cancer.
Copyright © 2008 J. L. Hatton and L. D. Yee. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
The peroxisome proliferator-activated receptor γ (PPARγ)i s
a ligand-activated transcription factor in the superfamily of
the steroid/thyroid nuclear hormone receptors, one of three
PPAR isotypes (α, β/δ,a n dγ)[ 1–3]. PPARs share a highly
conserved DNA-binding domain that matches with speciﬁc
DNA sequences known as peroxisome proliferator response
elements (PPREs), binding as a heterodimer with retinoid X
receptor(RXR)toinitiatetranscriptionoftargetgenes[4–6].
Highly expressed in adipose tissue, PPARγ is best known for
its important role in adipocyte diﬀerentiation [7–9].
PPARs were ﬁrst shown to be activated by compounds
inducing peroxisome proliferation [10, 11], then by a variety
of polyunsaturated fatty acids (PUFAs) in the micromolar
range [12]. PPARγ has a more restricted list of activators
compared to the other two isotypes, being more selective
to PUFAs compared to other fatty acids [13, 14]. Fatty acid
derivatives, such as 15-deoxy-Δ12,14-PGJ2 (15d-PGJ2)a n d
13- and 9-hydroxyoctadecadienoic acid (HODE), have also
been identiﬁed as activators of PPARγ [15–17]. Synthetic lig-
ands for PPARγ include the thiazolidinediones, a class of oral
hypoglycemic drugs that reduce hyperglycemia and hyperin-
sulinemia in insulin-resistant states [18]. Nonsteroidal anti-
inﬂammatory drugs (NSAIDs) such as ibuprofen are also
PPARγ ligands, but exhibit much lower binding aﬃnities in
comparison to thiazolidinediones [19].
A wealth of preclinical data supports a role for PPARγ
ligand therapy in many diﬀerent types of solid malignancies.
Experimental studies of human cancer cells and PPARγ have
focused primarily on the γ-activating eﬀects of thiazolidine-
diones, identifying PPARγ agonists as negative regulators of
cell growth and tumor progression. As a putative natural
ligand for PPARγ, 15d-PGJ2 also appears to have anticancer
eﬀe c t s .T r e a t m e n tw i t hP P A R γ ligands inhibits malignant
cell proliferation, with evidence for cell cycle arrest and
induction of apoptosis [20–25]. With the pivotal role of
PPARγ in adipocyte diﬀerentiation, PPARγ ligands have
been tested for diﬀerentiating eﬀects on malignant cells.
Changes consistent with induction of a more diﬀerentiated
cancer cell phenotype were detected in several tumor
model systems, including breast, colon, and liposarcoma
[9, 26–30].
The anticancer eﬀects of PPARγ agonists may also be
mediated in part via suppression of an angiogenic tumor
phenotype or angiogenic, inﬂammatory tumor microen-
vironment. PPARγ ligands appear to elicit antiangiogenic
eﬀects, via modulation of endothelial cell function and
growth [31–35]. The anti-inﬂammatory actions of PPARγ
ligands [36–38], which are of relevance to the treatment of
atherosclerosis and cardiovascular disease, may also prove
important for the treatment and prevention of cancer given
the association of chronic inﬂammation with increased
cancer risk [39].2 PPAR Research
Approved by the Food and Drug Administration for
treatmentoftype2diabetesmellitus,thiazolidinedioneshave
been evaluated for use as investigational cancer therapies.
The initial studies utilized troglitazone (Rezulin), which
was the ﬁrst thiazolidinedione in clinical use but ultimately
withdrawn from the US market in 2000 because of instances
of severe idiopathic liver disease [40]. Rosiglitazone (Avan-
dia) and pioglitazone (Actos) were thereafter used without
evidence of similar hepatotoxicity. The majority of clinical
trials of thiazolidinediones have been conducted in advanced
stages of disease. The following review examines the clinical
trial experience to date with thiazolidinediones in cancer.
2. MONOTHERAPY
SearchesofthePubMedandwww.clinicaltrials.govdatabases
identiﬁed nine clinical trials testing the eﬃcacy of thia-
zolidinediones as single agent therapy in cancer patients,
with the majority conducted in subjects with advanced
and/or metastatic stages of disease refractory to treatment.
Troglitazone was the drug of choice for human stud-
ies initiated prior to 2000, replaced by rosiglitazone or
pioglitazone in trials conducted after the withdrawal of
troglitazone from clinical use because of rare instances
of hepatotoxicity. Thiazolidinediones have been generally
administeredatthehighestrecommendeddosefortreatment
of diabetes mellitus, or slightly higher as with troglitazone at
800mg/day. Rather than mimic the generalized cytoxicity of
chemotherapeuticregimens,suchdosesmightselectivelytar-
get PPARγ-mediated eﬀects such as cellular diﬀerentiation,
growth inhibition, and induction of apoptosis.
2.1. Liposarcomas
As mesenchymal malignancies that arise from adipose tissue
[41, 42], liposarcomas express PPARγ at levels comparable
to normal adipose tissue [26]. PPARγ expression is a
distinguishing feature of liposarcomas relative to other soft
tissue sarcomas [43]. Treatment of primary cell strains
derived from human liposarcomas (two well-diﬀerentiated
liposarcomas and one intermediate grade myxoid/round cell
liposarcoma) with PPARγ and/or RXR ligands induced mor-
phologic and molecular changes consistent with adipocyte
diﬀerentiation [26]. These in vitro ﬁndings led to consid-
eration of thiazolidinediones for diﬀerentiation therapy of
liposarcomas.
Demetri et al. conducted an open label phase II clinical
trial to determine the eﬀects of troglitazone (800mg/day)
on tumor diﬀerentiation in patients with advanced and/or
metastatic liposarcoma [44]. In a report of three study
subjects, tumor samples obtained after the six week inter-
vention showed marked cytoplasmic lipid accumulation in
comparison to pretreatment biopsies, as well as morphologic
changes suggestive of mature adipocytes. The expression
of markers of adipocyte diﬀerentiation such as adipsin,
aP2, and PPARγ by Northern analysis increased following
treatment with troglitazone. Furthermore, cell proliferation
as assessed by the percentage of liposarcoma cells with Ki67
immunostaining decreased by two- to fourfold with the
study intervention. Three additional patients enrolled in
the study also had post-treatment biopsies with histologic
evidence of adipocyte diﬀerentiation and decreased cell
proliferation. The histologic subtypes treated in this study
ranged from intermediate to high grade, and the authors
raise the possibility that diﬀerentiation may prove diﬃcult
to assess in more diﬀerentiated tumors. This small pilot trial
of six subjects demonstrated a diﬀerentiating eﬀect of short-
term troglitazone therapy in advanced stage liposarcomas
providing the rationale for further clinical evaluation of
troglitazone and other PPARγ ligands in the management of
liposarcomas.
A second phase II trial evaluated the eﬀects of the
thiazolidinedione rosiglitazone (8mg administered as 4mg
twice daily) in nine patients with advanced, unresectable
liposarcomas [45]. Analyses of tumor samples obtained at
0, 6, and 12 weeks did not reveal changes in histopathology
or gene expression to support a diﬀerentiating eﬀect. By
quantitative RT-PCR, levels of adipsin, fatty acid-binding
protein (FABP), and PPARγ increased in only two of nine
tumors although in a somewhat inconsistent fashion. In
one of the patients with a dediﬀerentiated liposarcoma,
expression of PPARγ increased at week 12, FABP at week 6
and adipsin at weeks 6 and 12. However, disease progression
had been detected in this patient at 10 weeks of treatment,
such that the expression of diﬀerentiation markers did
not correlate with clinical beneﬁt. For the other subject,
upregulation of adipsin at week 12 was noted in a myxoid
liposarcoma, and treatment continued until progression of
disease at six months. Cell proliferation assessed by Ki67
immunostainingdidnotdecreasesigniﬁcantlywiththestudy
intervention,althoughthelowbaselinelevelsofproliferation
decreased further with rosiglitazone. Taken together the data
fail to support a role for rosiglitazone in the treatment of
liposarcoma at advanced stages.
The discrepant ﬁndings between the two phase II trials
of thiazolidinedione therapy may relate to diﬀerences in
the patient cohorts, tumors, and/or study agents. Whether
methodological issues contributed to the diﬀerences is not
clear. As surgery remains the mainstay of treatment for
liposarcomas, with limited therapeutic options for unre-
sectable, advanced disease, and investigation of PPARγ
ligands for adjuvant therapy of liposarcomas or control
of microscopic or minimal residual disease may still be
warranted.
2.2. Coloncancer
Considerable in vitro evidence exists to support the dif-
ferentiating and antiproliferative eﬀects of PPARγ ligand
therapy in coloncancer.PPARγ is highly expressed in human
colon tumor specimens and cancer cell lines [27, 46]. In
additiontogrowthinhibition,treatmentofcoloncancercells
with PPARγ ligands promotes tumor cell diﬀerentiation as
assessed by increased cytoplasmic to nuclear ratio and higher
levels of diﬀerentiation markers such as carcinoembryonic
antigen (CEA), villin, intestinal alkaline phosphatase, GOB-
4, and keratin 20 [27, 29, 47]. Although in vitro and in
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growth and diﬀerentiation of human colon cancer cell
lines [27], thiazolidinedione treatment with rosiglitazone
(BRL49653) or troglitazone stimulated rather than inhibited
the development of colon tumors in APCmin/+ mice [48,
49]. The loss of adenomatous polyposis coli (APC) tumor
suppressor gene function, which leads to accumulation of β-
catenin and enhanced Wnt pathway signaling, may account
for the contradictory ﬁndings of enhanced tumorigenesis in
this genetic versus xenograft model of colon cancer [50].
Interestingly, treatment with pioglitazone over a wide range
of doses suppressed intestinal tumor formation and hyper-
lipidemia in APC deﬁcient mice (APCmin/+ and Apc1309)
[51, 52]. Whether the use of diﬀerent thiazolidinediones or
experimental conditions led to the discrepant ﬁndings is
unclear.
Loss of function mutations in PPARG in colon cancer
may also account for variability in response to PPARγ
therapy. Four unique mutations of PPARγ were identiﬁed
in 55 sporadic colon cancers in exons 3 or 5; one yielding
a truncated protein with loss of the ligand binding domain
(c.472delA) and three causing defects in the binding of
synthetic or natural ligands (Q286P, K319X, and R288H)
[53]. A point mutation in exon 6, K422Q, was detected in
four human colon cancer cell lines that were resistant to the
antiproliferative and diﬀerentiating eﬀects of PPARγ ligands
[54]. However, K422Q mayhave limited clinical relevance,as
a study of 170 primary human colorectal cancers and 12 liver
metastases failed to detect the presence of K422Q mutations
[55].
A phase II trial evaluated troglitazone therapy
(800mg/day as a single dose) in 25 colon cancer patients
with lung and/or liver metastases [56]. Although well-
tolerated, troglitazone did not elicit objective tumor
responses. All patients had progression of disease with a
median progression-free survival of 1.6 months and median
overall survival of 3.9 months. Troglitazone does not seem
to have activity in advanced colon cancer, although the lack
of response may relate at least in part to the biologically
aggressive nature of Stage IV colon cancer that is refractory
to cytotoxic chemotherapy (the median number of prior
chemotherapy regimens was 3). Although the study was
not designed to assess troglitazone for possible tumor
promoting eﬀects, Kulke et al. urged caution in the use of
PPARγ agonists in colon cancer. In the future, advances
in the genomic proﬁling of colon cancer might allow for
identiﬁcation of susceptible colon cancer subtypes.
Colorectal cancer provides an excellent model of multi-
step progression in carcinogenesis, based on the acquisition
of biochemical, molecular, and genetic alterations that
transform normal epithelium to adenomatous polyps to
invasive cancer [57]. PPARγ ligands may have a role in
chemoprevention of colon cancer, depending on the speciﬁc
molecular and genetic subtype. Thiazolidinediones suppress
the development of aberrant crypt foci (ACF), a putative
precancerous lesion of the colon [58]. However, activation
of certain oncogenic signaling pathways at later stages of car-
cinogenesismayoverride thisregulatoryrole,assuggestedby
the APCmin/+ mouse studies [50]. Timing of PPARγ therapy
prior to certain initiating events in colon carcinogenesis may
thus prove to be useful for chemoprevention of colon cancer.
As suggested by the in vivo studies of thiazolidinediones in
min mice, use of PPARγ agonists in colon cancer prevention
may require identiﬁcation of high-risk individuals based on
genetic susceptibility as well as aberrant gene expression and
signal transduction.
Although the diﬀerentiating and antiproliferative eﬀects
of PPARγ activation form the basis for evaluating PPARγ
ligands for cancer therapy, the anti-inﬂammatory eﬀects of
PPARγ mayalsoberelevanttocoloncarcinogenesis.Chronic
inﬂammation is linked to carcinogenesis, and diagnoses of
inﬂammatory bowel disease (IBD), which includes Crohn’s
disease and ulcerative colitis, carry increased risk for colorec-
tal cancer [59]. PPARγ ligands repress cytokine production
by colon cancer cells and inhibit chemically-induced colitis
in murine models of inﬂammatory bowel disease [60–62].
These ﬁndings led to an open-label pilot trial of rosiglitazone
therapy (4mg taken twice daily) in patients with active
ulcerative colitis for 12 weeks, showing clinical improvement
in 8/15 (53%) patients of which 4 (27%) subjects had clinical
remission [63]. Two subjects required hospitalization for
worsening disease; other serious adverse events included
severe pharyngitis requiring hospitalization and nephritic
syndromeleadingtowithdrawal.Theincreasedriskforcolon
cancer in patients with ulcerative colitis relates to the severity
and duration of disease; by suppressing inﬂammation in the
colon, drugs such as the thiazolidinediones or other PPARγ
agonists might play a role in colon cancer prevention.
2.3. Breastcancer
In vitro and in vivo research studies support a role for
PPARγ agonists in breast cancer therapy. Thiazolidinedione
treatment of human breast cancer cells appears to induce
changes suggestive of terminal diﬀerentiation, resulting in
the inhibition of cell proliferation, suppression of keratin
19, mucin-1, and upregulation of maspin [28]. Troglitazone
also inhibited breast cancer growth in a xenograft animal
model [20]. Another synthetic ligand of PPARγ, GW7845,
had inhibitory eﬀects in a carcinogen-induced model of
mammary tumorigenesis [64]. Furthermore, PPARγ hap-
loinsuﬃciency (PPARγ+/−) conferred increased suscepti-
bility to dimethylbenz[a]antracene (DMBA)-induced mam-
mary carcinogenesis [65]. These studies suggest that PPARγ
ligands could serve as negative regulators of breast cancer
development and progression.
We and others have demonstrated PPARγ immunostain-
ing in human breast cancer specimens, as well as normal and
benign proliferative breast tissue [28, 66]. PPARγ appears to
be expressed in most if not all breast cancer cell lines, as well
as in normal and malignant breast tissue [20, 28, 66]. We
did not ﬁnd that the invasive, metastatic phenotype of the
breast cancer cells correlates with PPARγ expression levels,
gel shift mobility patterns, or relative sensitivity to PPARγ
ligands [67]. All of the cell lines tested (MCF-7, MDA-
MB-436, MDA-MB-231, and MDA-MB-435) responded to
thiazolidinedione treatment in transactivation assays, which
also led to inhibition of cell growth.4 PPAR Research
However, a Phase II trial of troglitazone in metastatic
breast cancer refractory to cytotoxic chemotherapy did not
demonstrate beneﬁcial eﬀects on disease progression [68]. In
twenty two Stage IV breast cancer patients with an 8-week
median treatment duration, troglitazone at 800mg/day did
not prevent disease progression. The median time on study
was 56 days, ranging from 11 to 134 days; 19/22 subjects
were removed from the study for objective or subjective
evidence of disease progression. There were no objective
responses, and only 3/21 (14%) subjects completing 8 weeks
of troglitazone therapy had stable disease. In patients with
elevated serum levels of CEA and/or CA27.29 at the onset
of the study, these tumor markers had continued to increase
despite 8 weeks of troglitazone. Burstein et al. note that
more selective criteria to target PPARγ therapy to the most
susceptible tumor type might be helpful. The lack of eﬀect
might have also related to an advanced stage of disease that
had become refractory to cytotoxic therapies.
To assess the eﬀects of PPARγ ligand therapy on breast
cancer, we conducted a pilot study of short-term adminis-
tration of rosiglitazone (4mg taken twice a day) to women
newly diagnosed with early stage breast cancer (Stages 0 to
II) during the two- to six-week period between diagnostic
biopsy and surgical removal of the cancer [69]. Thirty eight
women completed the study intervention without serious
adverse events; thirty four subjects had suﬃcient pre and
posttreatment tumor tissue for correlative analyses. By Ki67
immunostaining, short-term intervention with rosiglitazone
didnotleadtostatisticallysigniﬁcantdiﬀerencescellprolifer-
ation. We did not detect any somatic or germline mutations
in PPARG to account for diﬀerential tumor tissue responses
or lack of eﬀect. Comparing H&E-stained sections of tumor
before and after rosiglitazone therapy also failed to note
increased tumor cell diﬀerentiation by standard criteria of
tubule formation, mitotic activity, and nuclear morphology.
PPARγ expression in tumor samples was graded 0 to 3+ for
intensity of nuclear and cytoplasmic immunostaining, which
did not reﬂect an overall change in expression following
rosiglitazone therapy. Interestingly, nuclear expression of
PPARγ was signiﬁcantly reduced in a majority of the patients
whose pre-rosiglitazone PPARγ scores were 1+ or 2+ and
therefore assessable for increased or decreased levels of
expression, which raised the possibility of a PPARγ mediated
response in the tumor tissue.
Serum levels of adiponectin and indices of insulin sensi-
tivity increased with rosiglitazone, based on serum samples
obtained from seventeen subjects. Given the association
of lower levels of adiponectin and insulin resistance with
increased breast cancer risk [70–73], therapy with rosiglita-
zone or other PPARγ ligands may have a role in breast cancer
prevention. Of interest are potential eﬀects of rosiglitazone
therapy on nonepithelial components of the mammary
tumor microenvironment; unfortunately, pretreatment core
biopsy samples in our study had negligible to minimal
stromal, noncancerous tissue for any comparative analyses.
Although short-term intervention with rosiglitazone did
not alter the endpoint of cell proliferation, this pilot study
indicated the potential for other tumor tissue speciﬁc
eﬀects with evidence for downregulation of PPARγ protein
expression. Breast cancer is a family of diseases with
diverse molecular, genetic features, and PPARγ ligands may
aﬀect only certain subtypes. Indeed, breast cancer therapy
already encompasses molecularly targeted strategies, such
as tamoxifen for estrogen receptor positive cancer and
trastuzumab for tumors with HER-2/neu overexpression.
Variability in PPARγ-mediated eﬀects on cell proliferation
could arise from tumor heterogeneity in nuclear receptor
cross-talk, complement of cofactors, or mutated or aberrant
signaling pathways that override PPARγ signaling, leading
to an apparent lack of eﬀect of rosiglitazone [74–77]. For
example, in vitro studies indicate that estrogen receptor α
(ERα)c a nr e p r e s sP P A R γ signaling by binding to PPREs and
that PPAR/RXR heterodimers can competitively inhibit ER
binding at speciﬁc estrogen response elements (EREs) [74,
75]. In vitro administration of the PPARγ ligand 15-deoxy-
Δ12,14-prostaglandin J2 inhibited estrogen-mediated trans-
activation of ERE and estrogen-responsive gene expression
in MCF-7 breast cancer cells [78]. By immunohistochemical
analysis, PPARγ expression has been detected in 42%
(99/238) to 58% (101/170) of human breast cancer samples,
correlating positively with ER expression and improved
clinical outcome [78, 79]. Concomitant administration of
other drugs, such as estrogen in postmenopausal women
or thyroid hormone in patients with hypothyroidism, may
therefore aﬀect the interplay between nuclear receptors. Our
sample size did not support subset analyses, and further
studies are needed to identify speciﬁc molecular subtypes
of breast cancer that are susceptible to PPARγ ligand
therapy and crosstalk interactions. These data also raise
the possibility of PPARγ-mediated modulation of systemic
conditions relevant to breast cancer risk, such as serum
adiponectin and insulin resistance.
Breast cancer treatment and prevention may beneﬁt
from future studies of PPARγ therapy that address issues of
susceptible breast cancer subtypes, duration and timing of
intervention in the multistep process of mammary carcino-
genesis. Combination of PPARγ ligands with other agents
may enhance therapeutic eﬃcacy, as with RXR ligands for
synergism in PPARγ-RXR heterodimer-mediated signaling
[80]. Interestingly, inhibition of HER-2/neu tyrosine kinase
activity in a prostate cancer model prevents PPARγ degrada-
tion and thereby enhances susceptibility to PPARγ activators
such as R-etodolac [81]. Administration of a PPARγ agonist
in conjunction with trastuzumab (Herceptin), a humanized
monoclonal anti-HER-2/neu antibody used in the treatment
of metastatic and high-risk HER-2/neu+ breast cancer, could
also represent a novel combination of targeted therapies.
2.4. Prostatecancer
PPARγ is expressed in human prostate cancer cell lines
and human prostate cancer specimens [82]. In vitro and
in vivo studies also demonstrate the anticancer eﬀects of
PPARγ ligands on prostate cancer, including the reduction of
prostate speciﬁc antigen (PSA) levels in androgen responsive
LNCaP cells [82–85].
A phase II clinical study assessed the eﬀects of trogli-
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(n = 12) or androgen-independent prostate cancer (n = 29)
that had progressed following local treatment or androgen
deprivation therapy yet remained asymptomatic [82]. Four
patients with androgen-dependent cancers had a reduction
in serum PSA levels after onset of therapy, which were
measured every 4 weeks, with a greater than 50% decrease
in this tumor marker detected in one patient after 16 months
of troglitazone. PSA levels decreased less than 50% in four
patients with androgen-independent prostate cancer. The
median duration of troglitazone treatment was longer in the
androgen dependent (26.8 weeks) versus independent (14.3
weeks) group and could correlate with the more indolent
courseofdiseaseassociatedwiththeformer,aswellasgreater
susceptibility of this prostate cancer subtype. As suggested by
Muelleretal.,variabilityinresponsemightrelatetoactivated
mitogen-activated protein (MAP) kinase signaling leading to
phosphorylation and inactivation of PPARγ as well as the
possibility of somatic PPARG mutations.
Following from this initial study, a randomized placebo-
controlled Phase II trial of rosiglitazone (8mg/day) was
conducted in prostate cancer patients with progressive
disease evidenced by a rise in serum levels of PSA following
local treatment with radical prostatectomy and/or radiation
therapy[86].106menparticipatedinthismulti-institutional
study, with a median duration of 338 and 315 days of
treatment for rosiglitazone and placebo, respectively. Based
on serum PSA levels obtained every four weeks, rosiglitazone
did not signiﬁcantly increase the amount of time it took
serum levels of PSA to double or increase the time before
disease progression in men with prostate cancer. This trial
doesnotsupportaroleforrosiglitazoneinrecurrentprostate
cancer,evenifdetectedatthestageofbiochemical,nonradio-
graphic progression. Use of PPARγ ligands in prostate cancer
may require identiﬁcation of susceptible tumor subtypes
as well as consideration of intervention at earlier stages of
disease.
2.5. Thyroidcancer
The thyroid gland is comprised of follicle cells, which pro-
duce thyroglobulin as well as synthesize and store thyroxine,
triiodothyronine, and parafollicular C cells that produce
calcitonin. Papillary and follicular thyroid cancers arise
from follicle cells, comprising 80–90% of thyroid cancers.
Diﬀerentiated thyroid cancers usually retain the ability to
take up iodine, which serves as the basis for (1) radioactive
iodine treatments to ablate residual or metastatic disease and
(2) diagnostic screening via radioiodine scans [87]. These
thyroid cancers also produce thyroglobulin, and elevated
thyroglobulin levels following deﬁnitive therapy can signify
recurrent disease.
Normal, benign, and malignant thyroid tissues express
PPARγ, with dysregulated expression in thyroid cancers [88,
89].APAX8/PPARγ rearrangementhasbeennotedinhalfof
all follicular thyroid cancers, in which the resulting protein
has a loss of PPARγ function [90]. Treatment of human
thyroid cancer cells lines with thiazolidinediones inhibits cell
proliferation and induces increased expression of markers of
thyroid cell diﬀerentiation such as thyroglobulin, sodium-
iodine symporter, thyroperoxidase, and TSH receptor [91–
93].
These laboratory ﬁndings provided the basis for clinical
investigation of the diﬀerentiating eﬀects of PPARγ ligands
in thyroid cancer. Philips et al. conducted a pilot trial of
rosiglitazone therapy in ﬁve patients with thyroglobulin-
positive and radioiodine-negative thyroid cancer, a clinical
scenario suggestive of dediﬀerentiation of the thyroid cancer
[94]. After three months of rosiglitazone (4mg/day for one
month, then 8mg/day for 2 months), thyroglobulin levels
increased in 4 of 5 patients but only one subject had
faint radioiodine uptake to delineate two lung metastases.
Kebebew et al. also administered rosiglitazone (4mg/day for
1 week, then 8mg/day for an additional 7 weeks) to patients
with recurrent or progressive papillary or follicular thyroid
cancer who had elevated serum thyroglobulin levels and
negative radioiodine scans [95]. In this open label phase
II trial, 4 of 10 (40%) of the subjects had posttreatment
radioactive iodine scans showing uptake in the neck (n = 3)
and pelvis (n = 1). At the six month follow-up visit, serum
thyroglobulin changes did not reveal a consistent pattern,
with decreased (n = 2), increased (n = 5), and stable
(n = 3) levels. There were no complete responses, deﬁned
as increased radioiodine uptake and decreased thyroglobulin
levels. PPARγ expression in pretreatment tumor samples by
immunohistochemisty (formalin ﬁxed, paraﬃn-embedded
samples for eight patients) and real time quantitative RT-
PCR (frozen samples for four subjects) did not correlate
with the biological, biochemical responses. As noted in both
reports, serum thyroglobulin level is somewhat problematic
as a marker of diﬀerentiation in that increases could reﬂect
re-diﬀerentiation/apoptosis as well as tumor progression.
Futurestudieswillalsoneedtoaddressheterogeneityofstage
IV disease (e.g., some patients presented only with elevated
thyroglobulin whereas others had diﬀuse metastases), dose
level, duration of therapy, and intervention prior to develop-
ment of metastases.
3. COMBINATION THERAPY
Despite the wealth of preclinical evidence for the anticancer
eﬀects of PPARγ ligands in various types of cancer, thi-
azolidinediones appear largely ineﬀective as monotherapy
agents for treating advanced, disseminated stages of cancer.
However, cancer chemotherapy often involves the concomi-
tant and/or sequential administration of multiple drugs in
order to achieve maximal tumor cell kill and improved
disease-free and overall survival. Combinatorial drug regi-
mens may allow for additive if not synergistic eﬀects which
might also permit the use of lower dosages with decreased
side eﬀects. Preclinical studies show the potential beneﬁts of
combining PPARγ ligands with other anticancer agents. For
example, rosiglitazone treatment of A549 lung cancer cells
increases the expression of PTEN (phosphatase and tensin
homolog), which enhances the antiproliferative eﬀects of the
tyrosine kinase inhibitor geﬁtinib [96]. The combination of
rosiglitazone and platinum-based cytotoxic drugs such as
carboplatin and cisplatin synergistically inhibits the growth6 PPAR Research
of A549 lung cancer cells relative to single-agent therapy
[97]. Based on gene array analysis, rosiglitazone appears
to mediate the downregulation of metallothioneins, heavy
metal binding proteins involved in platinum drug resistance.
Lack of eﬀect of PPARγ ligand therapy may also relate
to repression of ligand activation, such as by histone
deacetylases(HDAC)whichcanformcomplexeswithPPARγ
to repress gene transcription of speciﬁc PPARγ target genes
[98]. Removal of HDAC-mediated transcriptional silencing
via HDAC inhibitors may allow activation of PPARγ,a s
suggestedbyinvitroandinvivostudiesofcombinedtherapy
ofprostatecancerwithHDACinhibitorsandPPARγ agonists
[85]. Inactivation of PPARγ via phosphorylation could also
occur in cancers with high levels of activity of mitogen-
activated protein kinase [99], and coadministration of
inhibitors of speciﬁc kinases might enhance the therapeutic
potential of a PPARγ agonist.
Novel treatment regimens combining pioglitazone with
the COX-2 inhibitor rofecoxib and low-dose continuous
chemotherapy drugs have been tested for eﬃcacy in aggres-
sive solid malignancies at advanced, progressive stages of
disease. In a pilot study of 6 patients with advanced malig-
nant vascular tumors that had progressed following surgery,
radiotherapy, and/or chemotherapy, treatment with piogli-
tazone (45mg/day), rofecoxib (25mg/day), and metronomic
trofosfamide(3×50mg/da y)resultedin2subjectswithcom-
plete responses, 1 with a partial response, and 3 with stable
disease [100]. The median progression-free survival was 7.7
months (rangeof2to 15 months),andthe averagetreatment
duration was 29.3, 21.7, and 23 weeks for pioglitazone,
rofecoxib, and trofosfamide, respectively. Interestingly, one
subject experienced regression of an extensive angiosarcoma
of the facial skin with initiation of therapy with pioglitazone
and rofecoxib alone. The Phase II trial of this treatment
regimen in a cohort of patients with progression of previ-
ously treated metastatic melanoma (n = 19) or soft tissue
sarcoma (n = 21) led to decreased tumor burden in 5
subjects and stabilization of disease in 6 subjects [101]. More
recently, a multi-institutional randomized clinical trial of
trofosfamide (50mg TID) versus trofosfamide (50mg TID)
plus rofecoxib (25mg/day) and pioglitazone (60mg/day)
of 76 patients with metastatic melanoma demonstrated
superiority of metronomic chemotherapy combined with
a COX-2 inhibitor and PPARγ ligand, with 0% versus 9%
progression-free survival [102]. Assessment of serum C reac-
tive protein (CRP) levels in 48 subjects participating in this
melanoma trial showed that those on the combined regimen
had a greater than 30% decrease in this proinﬂammatory
marker, suggesting that the anti-inﬂammatory eﬀects of
the drug combination may account for the improvement
in progression-free survival. Interestingly, PPARγ appears
to suppress the proinﬂammatory potential of monocytes
and macrophages [36, 103, 104], and thiazolidinediones
have been shown to decrease CRP levels [105]. Another
metronomic, low-dose chemotherapy regimen of either
capecitabine (1250mg/m2 twice daily for days 1–14 of
21 days) or temozolomide (50mg/m2/d ) combined with
pioglitazone (60mg/d) and rofecoxib (25mg/d) was tested
in patients who had developed recurrent high-grade gliomas
(10 with gliobastoma, 4 with anaplastic astrocytoma) fol-
lowing chemotherapy, surgery, and/or radiotherapy, with
21.5% overall progression-free survival at six months (20%
and 25% PFS for subjects with glioblastoma and anaplastic
gliomas, resp.) [106]. By immunostaining the expression of
COX-2, PPARγ, and CD31 in these high-grade gliomas did
not correlate with patient outcome; however, as recurrence
was diagnosed by magnetic resonance imaging, tumor tissue
obtained prior to disease progression might not accurately
represent target gene expression in the recurrent tumors.
The contribution of pioglitazone to the activity of these
combination regimens is diﬃcult to assess but may relate
to anti-inﬂammatory eﬀects as suggested by the CRP results
in metastatic melanoma. PPARγ ligands are also known to
exert suppressive eﬀects on angiogenesis in cancer [34]a n d
on malignant vascular cells [107], which may also enhance
the eﬀectiveness of metronomic chemotherapy regimens for
certain malignancies.
Combination with ligands to retinoid X receptor (RXR),
the heterodimer partner of PPARγ, may also augment the
anticancer eﬃcacy of PPAR ligand therapy. Treatment with
RXR ligands alone appears eﬃcacious in the treatment
of certain malignancies, and bexarotene (Targretin) is a
synthetic RXR-selective retinoid utilized in the treatment
of refractory cutaneous T-cell lymphoma [108]. A Phase
I study of bexarotene in patients with advanced cancer
did not show objective tumor responses but indicated the
potential for stable disease in 5 of 16 and 1 of 5 lung
and head and neck cancer patients, respectively [109]. In
a multi-institutional Phase II trial of bexarotene capsules
(MINT or Targretin Monotherapy in non-small-cell lung
cancer trial) in advanced non-small-cell lung cancer patients
who had failed two or more prior chemotherapy regimens,
bexarotene (400mg/m2/day) did not meet the intended aim
of a median survival of 6 months as third-line therapy;
however,thesubsetofsubjectswithtreatment-relatedhyper-
triglyceridemia (grade 1 to 4, 51%) and/or skin reactions
such as rash, pruritis, and erythema (grade 1 to 4, 28%)
had prolonged survival at one year of 30% and 34%, respec-
tively, compared to 18% and 19%, respectively, of patients
without these adverse events [110] .Ar o l ef o rb e x a r o t e n ea s
monotherapy is also demonstrated in preclinical models of
mammary carcinogenesis [111, 112]. A Phase II randomized
trial of 200 or 500mg/m2/day bexarotene in women with
metastatic breast cancer refractory to endocrine therapy
or chemotherapy showed clinical beneﬁt in the form of
complete/partial response and stable disease ≥6 months in
27 of 146 patients, with an objective response rate of 3 to 6%
[113].
To evaluate RXR-PPARγ ligand therapy for syner-
gism in cutaneous T-cell lymphoma, a small uncontrolled
study evaluated the addition of rosiglitazone to bexarotene
monotherapy in four patients with stable or progressive
cutaneous T-cell lymphoma, showing improvement in skin
score (50%) and pruritus (75%) [114]. Preclinical studies of
solid malignancies such as liposarcomas, breast, and colon
cancers also provide support for the greater eﬃcacy of
combined regimens of PPARγ and RXR ligands compared
to monotherapy [26, 80, 115]. In addition to increasedJ .L .H a t t o na n dL .D .Y e e 7
therapeutic beneﬁts, combination therapy may also allow for
lower doses and decreased toxicity.
Novel cancer agents that combine PPARγ agonism
with inhibition of other signaling pathways are also of
interest. LY293111 is a diaryl ether carboxylic acid derivative
that modulates multiple eicosanoid pathways, acting as a
leukotriene B4 antagonist, 5-lipoxygenase inhibitor, and
PPARγ agonist [116]. Phase I trials have identiﬁed the
maximally tolerated dose for continuous oral administration
of LY293111, both as a single agent and in combination with
irinotecan for solid malignancies [116]. Future clinical trials
with correlative tissue analyses may provide insight into the
speciﬁc contribution of PPARγ agonism to the therapeutic
potential of LY293111.
4. CANCER PREVENTION
PPARγ may function as a tumor suppressor during early
events of carcinogenesis. Thiazolidinediones or other PPARγ
ligands may have eﬃcacy during early stages of cancer
development, by targeting carcinogenesis prior to onset
of initiating events that are no longer subject to PPARγ
repression. Indeed, mutant APC function and dysregulated
β-catenin signaling in the APC+/min mice model of colon
carcinogenesis appear to abrogate responsiveness to PPARγ
activation [50]. Susceptibility to PPARγ ligands is possibly
limited to only certain premalignant conditions or individu-
als, and development of genomic strategies to properly apply
this chemopreventive option in an otherwise heterogeneous
high-risk population is needed.
In a phase II clinical trial of pioglitazone therapy for
dysplastic leukoplakia, a precursor lesion to invasive oral
cancer, pioglitazone administered for 3 months at 45mg/day
elicited a response in 70% of subjects (15/21) based on
bidimensional measurements of the oral lesions [117].
Although the degree of dysplasia increased in three subjects,
pioglitazone did not alter the degree of dysplasia in the
majority of patients. These ﬁndings raise the possibility that
PPARγ ligands may prove eﬃcacious for chemoprevention
of oral cancer by decreasing the extent of leukoplakia. The
lack of eﬀect on dysplasia suggests that pioglitazone may not
function as a diﬀerentiating agent for oral leukoplakia or at
least within the time frame of a three month intervention.
5. SAFETY AND TOXICITY ISSUES
Even though the risk-beneﬁt ratio of thiazolidinediones
for cancer therapy seems favorable for advanced stages of
disease, thiazolidinediones appear problematic as candidate
agents for chemoprevention rather than for treatment of
advanced, metastatic cancer. Use of thiazolidinediones in
adjuvant therapy for cancer patients who are otherwise
healthy but at increased risk for cancer recurrence would
also raise concerns if administered on a long-term basis as
for a chronic disease such as diabetes mellitus. Although
generally well-tolerated, thiazolidinediones such as rosigli-
tazone and pioglitazone are associated with body weight
gain as a result of increased adiposity and ﬂuid retention,
with the latter resulting in peripheral edema, anemia on
the basis of hemodilution, and increased risk of developing
congestive heart failure [118–120]. Controversy currently
exists regarding the cardiovascular safety of rosiglitazone,
with a recent meta-analysis of diﬀerent treatment trials of
rosiglitazone suggesting that rosiglitazone was associated
withasigniﬁcantincreaseintheriskofmyocardialinfarction
and cardiovascular death [121]. However, other studies have
not shown an increased risk of cardiovascular mortality,
including the interim analysis of the Rosiglitazone Evaluated
for Cardiac Outcomes and Regulation of Glycaemia in
Diabetes (RECORD) trial, a prospective trial of rosiglitazone
in type 2 diabetes mellitus [122, 123]. For postmenopausal
women, rosiglitazone therapy has also been linked to osteo-
porosis and risk of fracture [124]. Such side eﬀects are
concerning for healthy individuals contemplating cancer risk
reductionratherthantreatmentofdisease.Deﬁningtherisks
of thiazolidinediones will allow for avoidance of these drugs
in subjects at higher risk for these associated complications.
The carcinogenic potential of thiazolidinediones and
other PPARγ agonists is another point of controversy [125,
126]. Upon review of the carcinogenicity of PPARγ and dual
PPARα/γ agonists in development, the US Food and Drug
Administration has recommended two-year carcinogenicity
studies of new PPAR agonist drugs in rodents prior to initi-
ation of clinical trials longer than six months [127, 128]. As
discussed above, contradictory in vivo and in vitro ﬁndings
may relate to speciﬁc animal models or molecular, genetic
subtypes of certain cancers. Additionally, as diabetes and
insulin resistance have been linked to higher risk for certain
malignancies such as breast and colon cancer [72, 129, 130],
thiazolidinediones might even exert preventive eﬀects on
carcinogenesis by ameliorating the chronic inﬂammation
associated with dysregulated metabolism.
Postmarketing experience with pioglitazone and rosigli-
tazone has not shown signiﬁcantly increased cancer risk with
thesedrugs.ThePROactiveStudy(PROspectivepioglitazone
clinical trial In macrovascular events), which randomized
5238 patients with type 2 diabetes mellitus and cardiovascu-
lar or peripheral vascular disease to pioglitazone or placebo
for an average of 34.5 months, did not detect diﬀerences
in the overall number of malignancies [131]. Interestingly,
the pioglitazone treated group had more bladder tumors (14
versus 6) and fewer breast cancers (3 versus 11); however,
the timing of the cancer diagnoses relative to pioglitazone
use and the presence of confounding risk factors did not
support a causal relationship to the study drug. Use of thi-
azolidinediones was associated with 33% decreased risk for
lung cancer in a large retrospective database analysis of over
87,000 diabetic patients of 10 veteran aﬀairs medical centers,
without signiﬁcant risk reduction for colorectal and prostate
cancer [132]. Whether lung cancer is uniquely susceptible to
thiazolidinediones or other PPARγ agonists remains to be
determined; preclinical studies suggest a potential role for
PPARγ ligand therapy in the management of this disease
[133, 134]. In the preliminary report of a more recent
analysis of this Veteran Aﬀairs database, thiazolidinedione
use also correlated with 41 to 55% reduced risk for head
and neck squamous cell carcinoma [135]. Conversely, a
smaller retrospective study of 1003 diabetic subjects in the8 PPAR Research
Vermont diabetes information system database showed a
possible association of cancer with use of thiazolidinediones
and particularly rosiglitazone, based on self reported history
of malignancy of any type [136]. Prospective studies with
attention to confounding inﬂuences such as risk factors or
timing and duration of drug use relative to cancer diagnosis
areneededtoinvestigatethesepossibleassociationsandbasis
for the discrepant ﬁndings.
6. CONCLUSIONS
Based on the clinical experience to date, use of PPARγ ago-
nistsincancertherapywilllikelyrequireatargetedapproach,
with restriction to speciﬁc types of malignancies and/or
stage(s) of disease susceptible to enhanced PPARγ signaling.
Studies of PPARγ ligand therapy in cancer patients have
focusedlargelyonthiazolidinedionesapprovedfortreatment
of type 2 diabetes mellitus, administered at the high end of
doses tested for tolerability and insulin sensitizing eﬀects.
In phase II clinical trials, thiazolidinediones do not have
signiﬁcant activity in most cancers at advanced stages, which
may relate to the extent and burden of disease and aggressive
tumor phenotypes resistant to cytotoxic therapies. The lack
of eﬃcacy of thiazolidinediones in advanced, metastatic
disease may relate to the use of noncytotoxic dose levels;
alternatively, these drugs may not exert eﬀects at late stages
of cancer progression at any dose level. However, the
demonstration of diﬀerentiating eﬀects in some patients
suggests that a subset of patients might beneﬁt from
PPARγ ligand therapy. Thiazolidinediones and other PPARγ
agonists may ultimately prove eﬀective in combination with
standard cytotoxic agents or other molecularly targeted
therapies. Interventions at earlier stages of disease, including
premalignant or predisposing high-risk conditions, should
also be considered. Therapy administered in the adjuvant
setting, such as following surgical resection, or in situations
of microscopic rather than measurable disease may also
have greater eﬃcacy. The use of PPARγ ligands in earlier
stages of cancer or cancer prevention will require additional
research and/or drug development to address the questions
regardingthecarcinogenicpotentialandotheradverseeﬀects
of these drugs. Genetic and molecular proﬁling of human
cancers may in the future enable selection of a tumor
subtype susceptible to PPARγ agonists, as speciﬁc genotypes
and patterns of nuclear receptor and cofactor expression
might predict resistance or responsiveness to PPARγ signal
transduction.
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